The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

European Journal of Cancer

Volumn 46, Issue 3, 2010, Pages 517-525

  Armstrong, Andrew J ^a   Tannock, Ian F ^b   Wit, Ronald de ^c   George, Daniel J ^a   Eisenberger, Mario ^d   Halabi, Susan ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Castration resistant; Hormone refractory; Metastatic; Predictive factor; Prognostic factor; Prostate cancer; PSA response; Risk groups; Survival

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PAIN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALIDATION STUDY; VISCERAL METASTASIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MITOXANTRONE; NEOPLASM METASTASIS; NOMOGRAMS; ORCHIECTOMY; PREDNISONE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 75149172293     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.11.007     Document Type: Article

References (27)

1. Gondos A., Bray F., Hakulinen T., and Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 20 3 (2009) 564-573
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. CA Cancer J Clin 2008. Cancer statistics 58 2 (2008) 71-96
3. Tannock I.F., de W.R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 15 (2004) 1502-1512
4. Berthold D.R., Pond G.R., Soban F., de W.R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 2 (2008) 242-245
5. Ramiah V., George D.J., and Armstrong A.J. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 18 3 (2008) 303-308
6. Gignac G.A., Morris M.J., Heller G., Schwartz L.H., and Scher H.I. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer 113 5 (2008) 966-974
7. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., Carducci M.A., Tannock I., de W.R., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 25 (2007) 3965-3970
8. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de W.R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 21 (2007) 6396-6403
9. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 7 (2003) 1232-1237
10. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 19 (2002) 3972-3982
11. Buske C., Hoster E., Dreyling M., Hasford J., Unterhalt M., and Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 5 (2006) 1504-1508
12. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 8 (1999) 2530-2540
13. Petrylak D.P., Ankerst D.P., Jiang C.S., Tangen C.M., Hussain M.H., Lara Jr. P.N., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 8 (2006) 516-521
14. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 7 (2008) 1148-1159
15. Halabi S., Vogelzang N.J., Ou S.S., Owzar K., Archer L., and Small E.J. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 27 17 (2009) 2766-2771
16. Scher H.I., Warren M., and Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13 5 (2007) 1488-1492
17. Hussain M., Goldman B., Tangen C., Higano C.S., Petrylak D.P., Wilding G., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27 15 (2009) 2450-2456
18. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14 19 (2008) 6302-6309
19. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 11 (1999) 3461-3467
20. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1 3 (1975) 277-299
21. Hochberg Y., and Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 9 7 (1990) 811-818
22. Halabi S, Ou S, Vogelzang NJ, Scher H, Small EJ. A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl.):5113.
23. Halabi S. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. Urol Oncol: Seminars Orig Invest 26 3 (2008) 300-307
24. George D.J., Halabi S., Shepard T.F., Vogelzang N.J., Hayes D.F., Small E.J., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7 7 (2001) 1932-1936
25. Halabi S., Small E.J., Hayes D.F., Vogelzang N.J., and Kantoff P.W. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 21 3 (2003) 490-495
26. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 5748 (2005) 644-648
27. Thuret R., Massard C., Gross-Goupil M., Escudier B., Di P.M., Bossi A., et al. The postchemotherapy PSA surge syndrome. Ann Oncol 19 7 (2008) 1308-1311